Respiratory syncytial virus vaccine
Vaccine against respiratory syncytial virus / From Wikipedia, the free encyclopedia
A respiratory syncytial virus vaccine, or RSV vaccine, is a vaccine that protects against respiratory syncytial virus.[1] RSV affects an estimated 64 million people and causes 160,000 deaths worldwide each year.[2]
The RSV vaccines Arexvy (GSK),[3] Abrysvo (Pfizer),[4] and Mresvia (Moderna)[5] are approved for medical use in the United States.[6][7][8] Arexvy is approved for medical use in the United States,[3] in the European Union,[9][1] and in Canada for adults aged 60 years of age and older.[10] Arexy is approved in the US for adults aged 50–59 years of age who are at increased risk.[6][11][12] In June 2024, the US Centers for Disease Control and Prevention (CDC) updated its recommendation for the use of respiratory syncytial virus vaccine in people aged 60 years of age and older.[13] The CDC recommends that people who have not received the respiratory syncytial virus vaccine and are aged 75 years of age and older receive the respiratory syncytial virus vaccine; and that people who have not received the respiratory syncytial virus vaccine and are aged 60–74 years of age who are at increased risk of severe respiratory syncytial virus, meaning they have certain chronic medical conditions, such as lung or heart disease, or they live in nursing homes, receive the respiratory syncytial virus vaccine.[13][14]
Research to develop an RSV vaccine continued for decades; a 2013 study led to the approved vaccines.[15][16] Work on RSV vaccines also supported the rapid development of COVID-19 vaccines.[16][17]